Pablo E Pergola1, Chaim Charytan2, Dustin J Little3, Stefan Tham4, Lynda Szczech5, Robert Leong5, Steven Fishbane6. 1. Renal Associates PA, San Antonio, Texas. 2. NewYork-Presbyterian Queens, Flushing, New York. 3. Global Medicines Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals Research and Development, AstraZeneca Gaithersburg, Gaithersburg, Maryland. 4. Biostatistics, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals Research and Development, AstraZeneca Gothenburg, Gothenburg, Sweden. 5. FibroGen, Inc., San Francisco, California. 6. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York.
Abstract
Background: Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin by stimulating erythropoietin synthesis and improving iron availability through facilitation of iron uptake and/or release from stores. In this exploratory analysis, we assessed the effect of roxadustat treatment on laboratory parameters related to iron metabolism in patients with anemia of chronic kidney disease (CKD). Methods: Data were pooled from pivotal, randomized, phase 3 roxadustat trials: three placebo-controlled, double-blind trials in nondialysis-dependent (NDD) CKD and three open-label, active-comparator (epoetin alfa) trials in dialysis-dependent (DD) CKD. In this exploratory analysis, mean changes from baseline in hemoglobin, iron parameters, and hepcidin, and intravenous (iv) iron use were evaluated. Pooled results in NDD CKD and DD CKD patients are reported. Results: Overall, 4277 patients with NDD CKD and 3890 patients with DD CKD were evaluated. Hemoglobin increases with roxadustat treatment were accompanied by increases in serum iron and total iron-binding capacity (TIBC) and decreases in serum ferritin and hepcidin from baseline through week 52. With epoetin alfa, the hemoglobin increase was accompanied by decreases in serum ferritin and hepcidin, but serum iron decreased, and there was no change in TIBC. With placebo, there were no changes in hemoglobin, iron parameters, or hepcidin. During treatment, iv iron use was reduced with roxadustat versus placebo and epoetin alfa. Conclusions: In patients with NDD CKD and DD CKD, roxadustat treatment is associated with increases in serum iron and TIBC, accompanied by reduced hepcidin and indicative of improved iron kinetics. Patients treated with roxadustat achieved target hemoglobin levels with less iv iron use versus comparators. Practitioners treating patients with anemia of CKD with roxadustat should consider its unique effects when interpreting iron parameters.
Background: Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin by stimulating erythropoietin synthesis and improving iron availability through facilitation of iron uptake and/or release from stores. In this exploratory analysis, we assessed the effect of roxadustat treatment on laboratory parameters related to iron metabolism in patients with anemia of chronic kidney disease (CKD). Methods: Data were pooled from pivotal, randomized, phase 3 roxadustat trials: three placebo-controlled, double-blind trials in nondialysis-dependent (NDD) CKD and three open-label, active-comparator (epoetin alfa) trials in dialysis-dependent (DD) CKD. In this exploratory analysis, mean changes from baseline in hemoglobin, iron parameters, and hepcidin, and intravenous (iv) iron use were evaluated. Pooled results in NDD CKD and DD CKD patients are reported. Results: Overall, 4277 patients with NDD CKD and 3890 patients with DD CKD were evaluated. Hemoglobin increases with roxadustat treatment were accompanied by increases in serum iron and total iron-binding capacity (TIBC) and decreases in serum ferritin and hepcidin from baseline through week 52. With epoetin alfa, the hemoglobin increase was accompanied by decreases in serum ferritin and hepcidin, but serum iron decreased, and there was no change in TIBC. With placebo, there were no changes in hemoglobin, iron parameters, or hepcidin. During treatment, iv iron use was reduced with roxadustat versus placebo and epoetin alfa. Conclusions: In patients with NDD CKD and DD CKD, roxadustat treatment is associated with increases in serum iron and TIBC, accompanied by reduced hepcidin and indicative of improved iron kinetics. Patients treated with roxadustat achieved target hemoglobin levels with less iv iron use versus comparators. Practitioners treating patients with anemia of CKD with roxadustat should consider its unique effects when interpreting iron parameters.
Authors: Mark R Hanudel; Shirley Wong; Grace Jung; Bo Qiao; Victoria Gabayan; Anna Zuk; Tomas Ganz Journal: Kidney Int Date: 2021-03-31 Impact factor: 10.612
Authors: Megan L Noonan; Pu Ni; Rafiou Agoro; Spencer A Sacks; Elizabeth A Swallow; Jonathan A Wheeler; Erica L Clinkenbeard; Maegan L Capitano; Matthew Prideaux; Gerald J Atkins; William R Thompson; Matthew R Allen; Hal E Broxmeyer; Kenneth E White Journal: J Bone Miner Res Date: 2021-03-10 Impact factor: 6.741
Authors: Elizabeth Katherine Batchelor; Pinelopi Kapitsinou; Pablo E Pergola; Csaba P Kovesdy; Diana I Jalal Journal: J Am Soc Nephrol Date: 2020-02-10 Impact factor: 10.121
Authors: Megan L Noonan; Erica L Clinkenbeard; Pu Ni; Elizabeth A Swallow; Samantha P Tippen; Rafiou Agoro; Matthew R Allen; Kenneth E White Journal: Physiol Rep Date: 2020-06
Authors: Ughetta Del Balzo; Pierre E Signore; Gail Walkinshaw; Todd W Seeley; Mitchell C Brenner; Qingjian Wang; Guangjie Guo; Michael P Arend; Lee A Flippin; F Aisha Chow; David C Gervasi; Christian H Kjaergaard; Ingrid Langsetmo; Volkmar Guenzler; David Y Liu; Steve J Klaus; Al Lin; Thomas B Neff Journal: J Pharmacol Exp Ther Date: 2020-06-02 Impact factor: 4.030